Madrigal (MDGL) Q1 2026 earnings review
Volume Growth Collides with Pricing Reality
Madrigal's Rezdiffra achieved blockbuster run-rate status with $311.3M in Q1 2026 sales, but top-line momentum has hit a speed bump. Despite adding 6,000 new patients, revenue reversed sequentially (down 3% from Q4 25). This disconnect exposes the severe impact of newly enacted payer contracts, which pushed gross-to-net (GtN) discounts into the 'high 30% range'. Compounding the top-line pressure, profitability remains distant: net loss widened to $94.4M (-$3.25 EPS) as SG&A spending ballooned by 60% YoY to support endocrinology expansion and DTC campaigns. Madrigal is aggressively buying pipeline assets to build a moat, but the near-term financial picture shows a company paying heavily for market access and commercial scale.
🐂 Bull Case
The underlying volume growth is stable and robust. Madrigal expanded its patient base to 42,250 (up 2.5x YoY), proving that real-world demand remains high even through the seasonally difficult Q1 insurance reverification period.
Management continues to aggressively layer pipeline assets (now adding ARO-PNPLA3) to create future combo therapies. With Rezdiffra patents secured to 2045, they are building an enduring franchise.
🐻 Bear Case
A 16% sequential increase in the patient base resulted in a 3% sequential decline in revenue. Madrigal traded significant price concessions for first-line formulary access, shifting the burden entirely onto raw volume growth.
Generating $311M in revenue required $268M in SG&A expenses. The cost of acquiring and maintaining these patients is staggering, raising questions about terminal operating margins.
⚖️ Verdict: ⚪
Neutral. The commercial execution on patient acquisition is flawless, cementing Rezdiffra as the foundational MASH therapy. However, the sequential revenue contraction and ballooning operating expenses underscore the harsh economics of this launch phase.
Key Themes
Gross-to-Net Headwinds Erase Volume Gains
The long-telegraphed Q1 2026 pricing headwind materialized aggressively. Despite adding roughly 6,000 net new patients (a 16% volume expansion), total revenue reversed from $321.1M in 25Q4 to $311.3M in 26Q1. This confirms that the step-up in gross-to-net discounts (from the 20-30% range to the 'high 30% range') to secure first-line commercial payer access was steep enough to entirely wipe out a quarter of robust patient growth.
Patient Adoption Remains Steadily Strong
Patient growth remains stable and highly predictable. The company ended the quarter with 42,250 patients, maintaining a consistent pace of ~6,000 to ~6,500 net patient additions per quarter. Surviving Q1—typically plagued by insurance re-authorizations and deductible resets—without a drop in net patient additions is a strong testament to the drug's real-world adherence and physician support.
SG&A Expenses Decoupling from Revenue
SG&A spend is accelerating at a concerning rate. Expenses jumped to $268.5M, up 60% YoY. Management attributed this to endocrinology field force expansion and a direct-to-consumer (DTC) campaign. Spending $0.86 on SG&A for every $1.00 of revenue in the drug's second commercial year suggests significant commercial friction and pushes the timeline for operational profitability further into the future.
Aggressive Pipeline M&A Continues
Madrigal is using its cash position to build a massive MASH moat. The company recorded a $54.3M upfront R&D charge to license ARO-PNPLA3 (a clinical-stage siRNA) from Arrowhead. Following the acquisition of an oral GLP-1 and six other preclinical siRNA programs in prior quarters, management is pivoting from a single-asset company to a broad combination-therapy portfolio manager. This elevates execution risk as R&D complexity multiplies.
Other KPIs
Accelerating significantly from $44.2M a year ago. However, backing out the one-time $54.3M business development charge for the Arrowhead siRNA asset, core R&D was approximately $54.4M, representing a stable run-rate as the company funds the ongoing MAESTRO-NASH OUTCOMES trial and prepares new Phase 1 combination studies.
Decelerating from $988.6M at the end of 2025. The company burned approximately $170M in cash during the quarter, heavily influenced by the $54M Arrowhead licensing payment and high SG&A outlays. The balance sheet remains robust, but current burn rates demand eventual operating leverage.
Guidance
Maintained from prior quarters. This is a critical milestone as Madrigal seeks to prove it can formulate a well-tolerated combination therapy that leverages minimal weight loss to amplify Rezdiffra's anti-fibrotic effects.
Stable timeline for the drug-drug interaction study of their DGAT-2 inhibitor. This confirms the multi-pronged approach to combo therapies remains on track.
Key Questions
Gross-to-Net Plateau
We saw a 16% sequential increase in patients yield a 3% sequential decline in revenue. Is the 'high 30% range' gross-to-net discount now fully baked into the Q1 numbers, or should we expect further pricing degradation in Q2?
SG&A Leverage
SG&A reached $268M this quarter due to endocrinology expansion and DTC efforts. At what revenue run-rate do you expect SG&A growth to meaningfully decouple from top-line growth, allowing for operating margin expansion?
European Contribution
With the European launch underway in Germany, can you quantify what portion, if any, of the $311M in Q1 revenue came from ex-U.S. channels, and what the pricing dynamics look like there?
Patient Persistency
With patients now crossing the 2-year mark on commercial drug, what are the observed discontinuation rates, and how successfully are patients navigating the 12-month insurance reauthorization hurdle?